Invesco Biotechnology & Genome ETF (PBE) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores PBE 4.8 out of 10 — highest on Growth (9.7), lowest on Quality (1.8). It trades at 25.3 times earnings, against its own median of 22.1. Its ten largest holdings are 48% of the fund.
What stands out in PBE's data
Biotech and genome companies, tracked through a core index.
Analysts see stronger growth ahead than for most biotech peers — a bet on future drug pipelines.
Its forward growth estimate of 40% is double the category median of 20% and well above its own 3% historical median. Holds just 30 stocks.
A focused biotech sleeve that pairs with a broad health-care core.
Why did PBE move this week? It rose 1.9% in the week to October 9, 2026 — Novavax and Moderna drove it
PBE rose 1.9% in the week to October 9, 2026. The holdings that moved it most were Novavax (+21.9%), Moderna (+18.4%) and Gilead Sciences (+4.4%); Natera (−2.3%) pushed the other way.
How is PBE rated? ETF Copilot scores Invesco Biotechnology & Genome ETF (PBE) 4.8 out of 10
As of October 9, 2026, ETF Copilot scores Invesco Biotechnology & Genome ETF (PBE) 4.8 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 4.8 / 10
- Growth: 9.7 / 10
- Value: 2.5 / 10
- Risk: 3.4 / 10
- Quality: 1.8 / 10
- Return: 4.3 / 10
Is PBE expensive right now? It trades at 25.3 times earnings, against its own median of 22.1
As of October 9, 2026, PBE is more expensive than 67% of its own last 9 years.
Trailing 12 months, built from PBE's holdings. How we calculate this →
What's inside PBE?
What's inside PBE: Size (Large 40%, Mid 34%, Small 25%); Geography (International 3%, US 97%).
What are PBE's top holdings? The ten largest are 48% of the fund
Illumina, Natera, Biogen, Gilead Sciences, Amgen, Vertex Pharmaceuticals, Royalty Pharma, Regeneron Pharmaceuticals, Moderna and Novavax are PBE's largest holdings, in that order.
More concentrated than 51% of Health & Biotech ETFs.
Half of PBE's weight sits in its 11 largest positions, and once those weights are taken into account it behaves like 27 equally weighted holdings.
What is PBE's expense ratio? 0.59% a year
As of October 9, 2026, PBE charges 0.59% a year, yields 1.36% and holds $410M in assets across 30 positions.
| Measure | PBE |
|---|---|
| Expense ratio | 0.59% |
| Dividend yield | 1.36% |
| Assets under management | $410M |
| Holdings | 30 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “Invesco Biotechnology & Genome ETF (PBE) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/pbe
ETF Copilot Pro unlocks PBE's price and what each holding weighs.
Try Pro free →